Licensing Strategy

Licensing Out

Plethora is seeking to realise the potential of its development stage projects by forging development and marketing agreements with partners who have the resources and geographical coverage to commercialise these products internationally.

Current products available for licensing include:

• PSD597: A treatment for interstitial cystitis and painful bladder syndrome that has completed a Phase II clinical study
• PSD506: A novel treatment for overactive bladder that is currently in Phase II clinical development
• PSD503: A treatment for stress urinary incontinence which has completed a Phase II clinical study

Licensing In

Plethora actively pursues in-licensing opportunities in the field of urology and women’s health (both pharmaceuticals and medical devices). Products should be either in advanced stages of clinical developments or marketed products with commercial rights available for the UK market.

Contacts

To discuss any of the above opportunities please contact the Plethora business development team at:

Email: mail@plethorasolutions.co.uk

Tel: +44 (0) 20 3077 5400

Fax: +44 (0) 20 3077 5440